TRAVASOL- leucine, phenylalanine, lysine hydrochloride, methionine, isoleucine, valine, histidine, threonine, tryptophan, alanine, glycine, arginine, proline, tyrosine, serine injection

Travasol by

Drug Labeling and Warnings

Travasol by is a Prescription medication manufactured, distributed, or labeled by Baxter Healthcare Corporation, PACE ANALYTICAL INC.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    TRAVASOL is indicated as a source of amino acids for patients requiring parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. TRAVASOL may be used to treat negative nitrogen balance in patients.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Important Preparation Information

    TRAVASOL is supplied as a pharmacy bulk package for admixing only and is not for direct intravenous infusion. Prior to administration, TRAVASOL must be transferred to a separate PN container, diluted and used as an admixture with or without dextrose, electrolytes and/or lipid emulsion.

    • The key factor in preparation is careful aseptic technique to avoid inadvertent touch contamination during mixing of solutions and addition of other nutrients.
    • Do not remove container from overpouch until ready to use.
    • Tear protective overpouch across top at slit and remove solution container. Small amounts of moisture may be found on the solution container from water permeating from inside the container. The amount of permeated water is insufficient to affect the solution significantly. If larger amounts of water are found, the container should be checked for tears or leaks.
    • Inspect TRAVASOL prior to use. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Evaluate the following:
      • o If the outlet port protector is damaged, detached, or not present, discard container.
      • o Check to ensure the solution is clear, colorless or slightly yellow. Discard if the solution is bright yellow or yellowish brown.
      • o Check for minute leaks by squeezing inner container. If leaks are found, discard container.
    • TRAVASOL is intended for use in the preparation of sterile, intravenous admixtures. Because additives may be incompatible with TRAVASOL, evaluate all additions for compatibility.

    2.2 Administration Instructions

    •   TRAVASOL is for admixing use only. It is not for direct intravenous infusion. Prior to administration, TRAVASOL must be diluted with other compatible intravenous fluids or used as an admixture with or without dextrose, electrolytes and/or lipid emulsion.
    •  
    • TRAVASOL is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). The key factor in the preparation is careful aseptic technique to avoid inadvertent touch contamination during mixing of solutions and addition of other nutrients.
    •  
    • TRAVASOL is for admixing with dextrose injection and/or lipid emulsions using a PN container.
    •  
    • When TRAVASOL is admixed with dextrose injection and/or lipid emulsion, the choice of a central or peripheral venous route should depend on the osmolarity of the final infusate. Solutions with greater than 5% dextrose or with osmolarity of 900 mOsm/L or greater must be infused through a central venous catheter [see Warnings and Precautions (5.6)].
    •  
    • Use a dedicated line for PN solutions.
    •  
    • Intravenous lipid emulsions can be infused concurrently into the same vein as TRAVASOL-dextrose solutions by a Y-connector located near the infusion site; flow rates of each solution should be controlled separately by infusion pumps.
    •  
    • For administration without lipid emulsion, use a 0.22 micron in-line filter. If lipid emulsion is also administered, use a 1.2 micron in-line filter
    •  
    • To prevent air embolism, use a non-vented infusion set or close the vent on a vented set, avoid multiple connections, do not connect flexible containers in series, fully evacuate residual gas in the container prior to administration, do not pressurize the flexible container to increase flow rates, and if administration is controlled by a pumping device, turn off pump before the container runs dry.
    •  
    • If admixed or infused with lipid emulsion, do not use administration sets and lines that contain di-2-ethylhexyl phthalate (DEHP). Administration sets that contain polyvinyl chloride (PVC) components have DEHP as a plasticizer.
    •  
    • Calcium and phosphate ratios must be considered. Excess addition of calcium and phosphate, especially in the form of mineral salts, may result in the formation of calcium phosphate precipitates [see Warnings and Precautions (5.1)].
    •  
    • Prior to infusion, visually inspect the diluted PN solution containing TRAVASOL for particulate matter. The solution should be clear and there should be no precipitates. A slight yellow color does not alter the quality and efficacy of this product. If lipid has been added, ensure the emulsion has not separated. Separation of the emulsion can be visibly identified by a yellowish streaking or the accumulation of yellowish droplets in the mixed emulsion. Discard the admixture if any of the above are observed.

    2.3 Preparation Instructions for Admixing Using a Parenteral Nutrition (PN) Container

    • Open by tearing protective overwrap across top at slit and remove solution container. If overpouch has been previously opened or is damaged, discard solution.
    • If the outlet port protector is damaged, detached, or not present, discard the container.
    • Some opacity of the plastic due to moisture absorption during the sterilization process may be observed.
    • Check for minute leaks by squeezing the inner container firmly. If leaks are found, discard solution.
    • Once the protective foil overwrap has been removed, suspend container from eyelet support.
    • Remove plastic protector from outlet port at bottom of container.
    • Attach solution transfer set. Refer to complete directions accompanying set. Note : The closure shall be penetrated only one time with a suitable sterile transfer device or dispensing set which allows measured dispensing of the contents.
    • Prepare the admixture into the PN container using strict aseptic techniques to avoid microbial contamination.
    • Do not add the lipid emulsion to the PN container first; destabilization of the lipid emulsion may occur from such an admixture.
    • TRAVASOL may be mixed with dextrose injection and/or lipid emulsion. The following proper mixing sequence must be followed to minimize pH related problems by ensuring that typically acidic dextrose injections are not mixed with lipid emulsions alone:
      • 1. Transfer dextrose injection to the parental nutrition pooling container.
      • 2. Transfer amino acid injection
      • 3. Transfer lipid emulsion
    • Transfer Travasol to separate PN container for admixing . Because additives may be incompatible, evaluate all additions to the PN container for compatibility and stability of the resulting preparation. Consult with pharmacist, if available. Questions about compatibility may be directed to Baxter. If it is deemed advisable to introduce additives to the PN container, use aseptic technique.
    • Use gentle agitation during admixing to minimize localized concentration effects; shake containers gently after each addition.
    • Alternatively, simultaneous transfer to the PN container of TRAVASOL, dextrose injection and lipid emulsion is also permitted.
    • The prime destabilizers of emulsions are excessive acidity (such as pH below 5) and inappropriate electrolyte content. Give careful consideration to additions of divalent cations (Ca++ and Mg++), which have been shown to cause emulsion instability. Amino acid solutions exert buffering effects that protect the emulsion.
    • Inspect the final PN solution containing TRAVASOL to ensure that:
      • o Precipitates have not formed during the mixing or addition of additives
      • o The emulsion has not separated. Separation of the emulsion can be visibly identified by a yellowish streaking or the accumulation of yellowish droplets in the admixed emulsion.
      • o Discard the admixture if any of the above are observed.
    • For single use only. Discard used container of TRAVASOL.
    • Use for admixing should be limited to up to 4 hours at room temperature (25ºC/77ºF) after the container closure has been penetrated.
    • Admixtures should be used promptly with storage under refrigeration 2° to 8°C (36° to 46°F) not to exceed 24 hours and must be completely used within 24 hours after removal from refrigeration. Any mixture remaining must be discarded.
    • Do not connect flexible containers in series to avoid air embolism due to possible residual gas contained in the primary container.
    • Air embolism can result if residual gas in the container is not fully evacuated prior to administration if the flexible container is pressurized to increase flow rates.
    • If administration is controlled by a pumping device, discontinue pumping action before the container runs dry to avoid air embolism.
    • For automated compounding, refer to Instructions for Use of the applicable compounder.
    • Containers should not be written on directly since ink migration has not been investigated. Affix accompanying label for date and time of entry.

    2.4 Dosing Considerations

    • TRAVASOL is for admixing only. It is not for direct intravenous infusion. Prior to administration, TRAVASOL must be diluted with other compatible intravenous fluids or used as an admixture with or without dextrose, electrolytes and lipid emulsion.
    • TRAVASOL is a part of the PN regimen which also includes dextrose, electrolytes, and lipid emulsion. Protein, caloric, fluid and electrolyte requirements all need to be taken into consideration when determining individual patient dosage needs.
    • The dosage of the final PN solution containing TRAVASOL must be based on the concentrations of all components in the solution and the recommended nutritional requirements [see Dosage and Administration (2.5, 2.6, 2.7)]. Consult the prescribing information of all added components to determine the recommended nutritional requirements for dextrose and lipid emulsion, as applicable.
    • The dosage of TRAVASOL should be individualized based on the patient’s clinical condition (ability to adequately metabolize amino acids), body weight and nutritional/fluid requirements, as well as additional energy given orally/enterally to the patient. Prior to initiating parenteral nutrition the following patient information should be reviewed: review of all medications, gastrointestinal function and laboratory data (such as electrolytes (including magnesium, calcium, and phosphorus), glucose, urea/creatinine, liver panel, complete blood count and triglyceride level (if adding lipid emulsion)).
    • Lipid emulsion administration should be considered with prolonged use (more than 5 days) of PN and is required in order to prevent essential fatty acid deficiency (EFAD). Serum lipids should be monitored for evidence of EFAD in patients maintained on fat-free PN. See complete prescribing information of lipid emulsion.
    • Prior to administration of PN solution containing TRAVASOL, correct severe fluid, electrolyte and acid-base disorders.
    • In many patients, provision of adequate calories in the form of hypertonic dextrose may require the administration of exogenous insulin to prevent hyperglycemia and glycosuria.
    • Monitor levels of serum potassium during PN therapy. It may be necessary to add additional potassium to the PN admixture.

    2.5 Recommended Dosage in Adults

    •   The recommended adult daily dosage of TRAVASOL and the nutritional requirements for protein (nitrogen) are shown in Table 1.
    •  
    •   As a component of PN, TRAVASOL provides 0.1 g protein/mL, which corresponds to 0.0165 g nitrogen/mL.
    •  
    •   As indicated on an individual basis, vitamins, electrolytes, trace elements and other components (including dextrose, electrolytes and lipid emulsion) can be added to the PN solution to meet nutrient needs and prevent deficiencies and complications from developing.
    •   A maximum fluid supply of 40 mL/kg/day of PN solution, based on protein, should not be exceeded in adult patients; this volume does not take carbohydrates or electrolytes into consideration.
    •  
    •   The flow rate of the PN solution must be adjusted taking into account the dose being administered, the daily volume intake, and the duration of the infusion. The flow rate should be increased gradually and governed, especially during the first few days of therapy, by the patient’s tolerance to dextrose. Daily intake of TRAVASOL and dextrose should be increased gradually to the maximum required dose as indicated by frequent determinations of blood glucose levels.
    Table 1. Recommended Daily Dosage in Adults
  • * Protein is provided as amino acids. When infused intravenously, amino acids are metabolized and utilized as the building blocks of protein.
  • † A maximum fluid supply of 40 mL/kg/day of parenteral nutrition solution should not be exceeded in adult patients.
  • ‡ Includes patients requiring more than 2 to 3 days in the intensive care unit with organ failure, sepsis or postoperative major surgery. Do not use in patients with conditions that are contraindicated [see Contraindications (4)].
    		•
    •   Adult Patient Population
    •   Recommended
      Protein      * Requirement
      (g/kg/day)      1
    •   Corresponding Nitrogen Requirement
      (g/kg/day)
    •   Recommended Daily Dosage of TRAVASOL
      (mL/kg/day)      †
    •   Stable Patients
    •   0.8 to 1.0
    •   0.13 to 0.16
    •   8 to 10
    •   Critically Ill Patients‡
    •   1.5 to 2.0
    •   0.24 to 0.32
    •   15 to 20

    2.6 Dosage Modifications in Patients with Renal Impairment

    Prior to administration, correct severe fluid or electrolyte imbalances. Closely monitor serum electrolyte levels and adjust the volume of parenteral nutrition administered as required [see Warnings and Precautions (5.10)].

    Patients with renal impairment not needing dialysis require 0.6 to 0.8 g of protein/kg/day. Serum electrolyte levels should be closely monitored. Patients on hemodialysis or continuous renal replacement therapy should receive 1.2 to 1.8 g of protein/kg/day up to a maximum of 2.5 g of protein/kg/day based on nutritional status and estimated protein losses.2

    2.7 Recommended Dosage in Pediatric Patients

    The dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low weight infants, because of the increased risk of hyperglycemia/hypoglycemia [see Use in Specific Populations (8.4)]. Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants. The infusion rate and volume should be determined by the consulting physician experienced in pediatric intravenous fluid therapy.

    In pediatric patients, TRAVASOL is dosed on the basis of protein provided as amino acids. The recommended dosage, by age group is provided in .

    Infusion rates are based on protein and do not take carbohydrates, fluid or electrolytes into consideration.

    TRAVASOL does not contain the amino acids cysteine and taurine, considered conditionally essential for neonates and infants. If possible, these amino acids should be added to the PN admixture if used in this pediatric population.

    Table 2. Recommended Daily Dosage in Pediatric Patients
    AgeRecommended Proteina Requirement (g/kg/day)1Corresponding Nitrogen Requirement (g/kg/day)Recommended Daily Dosage of TRAVASOL (mL/kg/day)

    Preterm and term infants less than 1 month of age

    3 to 4

    0.48 to 0.64

    30 to 40

    Pediatric patients 1 month to less than 1 year of age

    2 to 3

    0.32 to 0.48

    20 to 30

    Pediatric patients 1 to 10 years of age

    1 to 2

    0.16 to 0.32

    10 to 20

    Pediatric patients greater than 10 to less than 17 years of age

    0.8 to 1.5

    0.13 to 0.24

    8 to 15
    • a Protein is provided as amino acids. When infused intravenously, amino acids are metabolized and utilized as the building blocks of protein.

    2.8 Discontinuation of Parenteral Nutrition

    To reduce the risk of hypoglycemia after discontinuation, a gradual decrease in flow rate in the last hour of infusion should be considered when administering PN solutions containing dextrose.

  • 3 DOSAGE FORMS AND STRENGTHS

    TRAVASOL is a sterile solution available in 500 mL, 1000 mL, and 2000 mL flexible containers, which contain essential and nonessential amino acids. describes the individual components of TRAVASOL.

    Table 3. Ingredients per 100 mL of TRAVASOL
    Amino Acids10 g
  • * Balanced by ions from amino acids.
  • † Derived from pH adjustment with glacial acetic acid.
  • ‡ Contributed by the Lysine Hydrochloride.
    		•

    Total Nitrogen

    1.65 g

    Essential Amino Acids

    Leucine

    730 mg

    Isoleucine

    600 mg

    Lysine (added as the hydrochloride salt)

    580 mg

    Valine

    580 mg

    Phenylalanine

    560 mg

    Histidine

    480 mg

    Threonine

    420 mg

    Methionine

    400 mg

    Tryptophan

    180 mg

    Nonessential Amino Acids

    Alanine

    2.07 g

    Arginine

    1.15 g

    Glycine

    1.03 g

    Proline

    680 mg

    Serine

    500 mg

    Tyrosine

    40 mg

    Anion profiles per liter*

    Acetate†

    88 mEq

    Chloride‡

    40 mEq

    pH (Range); pH adjusted with glacial acetic acid

    6.0 (5.0 to 7.0)

    Osmolarity (calc)

    998 mOsm/L
  • 4 CONTRAINDICATIONS

    The use of TRAVASOL is contraindicated in:

    • Patients with known hypersensitivity to one or more amino acids [see Warnings and Precautions (5.2)].
    • Patients with inborn errors of amino acid metabolism due to risk of severe metabolic or neurologic complications.
    • Patients with pulmonary edema or acidosis due to low cardiac output.
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Pulmonary Embolism due to Pulmonary Vascular Precipitates

    Pulmonary vascular precipitates causing pulmonary vascular emboli and pulmonary distress have been reported in patients receiving PN, including TRAVASOL. In some cases, fatal outcomes due to pulmonary embolism have occurred. TRAVASOL contains no added phosphorus. Patients, especially those with hypophosphatemia, may require the addition of phosphate. To prevent hypocalcemia, calcium supplementation should always accompany phosphate administration. Excessive addition of calcium and phosphate increases the risk of the formation of calcium phosphate precipitates. Precipitates have been reported even in the absence of phosphate salt in the solution. Precipitation following passage through an in-line filter and suspected in vivo precipitate formation has also been reported. If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation. In addition to inspection of the solution [see Dosage and Administration (2.1, 2.2, 2.3, 2.4)], the infusion set and catheter should also periodically be checked for precipitates.

    5.2 Hypersensitivity Reactions

    Hypersensitivity reactions including anaphylaxis have been reported with PN solutions containing TRAVASOL. Stop the infusion immediately and treat patient accordingly if any signs or symptoms of a hypersensitivity reaction develop. Signs or symptoms may include: hypotension, hypertension, peripheral cyanosis, tachycardia, dyspnea, vomiting, nausea, urticaria, rash, pruritus, erythema, hyperhidrosis, pyrexia, and chills.

    5.3 Risk of Infections

    Patients who require PN are at high risk of infections because the nutritional components of these solutions can support microbial growth. Infection and sepsis may also occur as a result of the use of intravenous catheters to administer PN.

    The risk of infection is increased in patients with malnutrition-associated immunosuppression, hyperglycemia exacerbated by dextrose infusion, long-term use and poor maintenance of intravenous catheters, or immunosuppressive effects of other concomitant conditions, drugs, or other components of the parenteral formulation (e.g., lipid emulsion).

    To decrease the risk of infection, ensure aseptic technique in catheter placement and maintenance, as well as aseptic technique in the preparation and administration of the nutritional formula.

    Monitor for signs and symptoms (including fever and chills) of early infections, including laboratory test results (including leukocytosis and hyperglycemia) and frequent checks of the parenteral access device and insertion site for edema, redness and discharge.

    5.4 Refeeding Syndrome

    Refeeding severely undernourished patients may result in refeeding syndrome, characterized by the intracellular shift of potassium, phosphorus, and magnesium as the patient becomes anabolic. Thiamine deficiency and fluid retention may also develop. To prevent these complications, monitor severely undernourished patients and slowly increase nutrient intakes.

    5.5 Hyperglycemia or Hyperosmolar Hyperglycemic State

    Administration of PN solutions containing dextrose in patients with diabetes mellitus, impaired glucose tolerance may worsen hyperglycemia. Administration of dextrose at a rate exceeding the patient’s utilization rate may lead to hyperglycemia, coma, and death. Patients with underlying confusion and renal impairment who receive dextrose infusions, may be at greater risk of developing hyperosmolar hyperglycemic state. Monitor blood glucose levels and treat hyperglycemia to maintain optimum levels while administering PN solutions containing dextrose. Insulin may be administered or adjusted to maintain optimal blood glucose levels during administration of PN solutions containing dextrose.

    5.6 Vein Damage and Thrombosis

    TRAVASOL must be diluted and used as an admixture with or without dextrose, electrolytes and/or lipid emulsion. It is not for direct intravenous infusion. Solutions containing more than 5% dextrose or with an osmolarity of 900 mOsm/L or greater must be infused through a central catheter [see Dosage and Administration (2.2)]. The infusion of hypertonic nutrient injections into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis.The primary complication of peripheral access is venous thrombophlebitis, which manifests as pain, erythema, tenderness or a palpable cord. Remove the catheter as soon as possible, if thrombophlebitis develops.

    5.7 Hepatobiliary Disorders

    Hepatobiliary disorders are known to develop in some patients without preexisting liver disease who receive PN, including cholecystitis, cholelithiasis, cholestasis, hepatic steatosis, fibrosis and cirrhosis, possibly leading to hepatic failure. The etiology of these disorders is thought to be multifactorial and may differ between patients.

    Increase in blood ammonia levels and hyperammonemia may occur in patients receiving amino acid solutions, including TRAVASOL. In some patients this may indicate hepatic insufficiency or the presence of an inborn error of amino acid metabolism [see Contraindications (4) and Use in Specific Populations (8.4)].

    Monitor liver function parameters and ammonia levels. Patients developing signs of hepatobiliary disorders should be assessed early by a clinician knowledgeable in liver diseases in order to identify possible causative and contributory factors, and possible therapeutic and prophylactic interventions.

    5.8 Aluminum Toxicity

    TRAVASOL contains no more than 25 mcg/L of aluminum. However, with prolonged parenteral administration in patients with renal impairment, the aluminum contained in TRAVASOL may reach toxic levels. Preterm infants are at a greater risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

    Patients with renal impairment, including preterm infants, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day, accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

    5.9 Risk of Parenteral Nutrition Associated Liver Disease

    Parenteral Nutrition Associated Liver Disease (PNALD) has been reported in patients who receive PN for extended periods of time, especially preterm infants, and can present as cholestasis or steatohepatitis. The exact etiology is unknown and is likely multifactorial. If patients treated with PN solutions containing TRAVASOL develop liver test abnormalities consider discontinuation or dosage reduction.

    5.10 Electrolyte Imbalance and Fluid Overload

    Patients with renal impairment, such as pre-renal azotemia, renal obstruction, and protein-losing nephropathy may be at increased risk of electrolyte and fluid volume imbalance. Patients with cardiac insufficiency and pulmonary congestion are susceptible to excess fluid accumulation. Use PN solutions containing TRAVASOL with caution in patients with cardiac insufficiency or renal impairment. The dosage of PN may require adjustment with specific attention to fluid, protein, and electrolyte content in these patients.

    Monitor renal function parameters. Patients developing signs of renal impairment should be assessed early by a clinician knowledgeable in renal disease in order to determine the appropriate PN dosage and other treatment options.

    5.11 Monitoring/Laboratory Tests

    Monitor fluid and electrolyte status, serum osmolarity, blood glucose, liver and kidney function, blood count and coagulation parameters throughout treatment. If electrolyte levels are severely elevated, stop PN containing TRAVASOL until levels have been corrected.

  • 6 ADVERSE REACTIONS

    The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information.

    The following adverse reactions from voluntary reports or clinical studies have been reported with TRAVASOL. Because many of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    • Metabolic acidosis
    • Alkalosis
    • Osmotic diuresis and dehydration,
    • Rebound hypoglycemia
    • Hypo and hyper vitaminosis
  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Limited published data with injectable amino acids solutions, including TRAVASOL in pregnant women are not sufficient to inform a drug associated risk for adverse developmental outcomes. However, malnutrition in pregnant women is associated with adverse maternal and fetal outcomes [see Clinical Considerations]. Animal reproduction studies have not been conducted with injectable amino acids solutions, including TRAVASOL.

    The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. However, the background risk in the U.S. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies.

    Clinical Considerations

    Disease-Associated Maternal and/or Embryo-Fetal Risk

    Severe malnutrition in pregnant women is associated with preterm delivery, low birth weight, intrauterine growth restriction, congenital malformations and perinatal mortality. Parenteral nutrition should be considered if a pregnant woman’s nutritional requirements cannot be fulfilled by oral or enteral intake.

    8.2 Lactation

    Risk Summary

    There are no data available to assess the presence of injectable amino acids, including TRAVASOL in human milk, the effects of TRAVASOL on the breastfed infant or the effects on milk production. The lack of clinical data during lactation precludes a clear determination of the risk of TRAVASOL to a child during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TRAVASOL and any potential adverse effects on the breastfed child from TRAVASOL or from the underlying maternal condition.

    8.4 Pediatric Use

    Neonates, especially premature infants with low birth weight, are at increased risk of developing hypo- or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose solutions to ensure adequate glycemic control in order to avoid potential long term adverse effects [see Dosage and Administration (2.7)].

    Plasma electrolyte concentrations should be closely monitored in the pediatric patients who may have impaired ability to regulate fluids and electrolytes.

    Hyperammonemia is of special significance in infants (birth to two years). This reaction appears to be related to a deficiency of the urea cycle amino acids of genetic or product origin. It is essential that blood ammonia be measured frequently in infants [see Warnings and Precautions (5.7)].

    Because of immature renal function, preterm infants receiving prolonged PN treatment with TRAVASOL may be at risk of aluminum toxicity [see Warnings and Precautions (5.8)].

    Patients, including pediatric patients, may be at risk for Parenteral Nutrition Associated Liver Disease (PNALD) [see Warnings and Precautions (5.9)].

    8.5 Geriatric Use

    Clinical studies with TRAVASOL have not been performed to determine whether subjects aged 65 and over respond differently from other younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

    In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy.

    8.6 Renal Impairment

    In patients with impaired renal function, PN solutions containing TRAVASOL should be administered with caution. Frequent clinical evaluation and laboratory tests to monitor renal function such as serum electrolytes (especially phosphate and potassium) and fluid balance should be conducted [see Dosage and Administration (2.6), Warnings and Precautions (5.10)].

    8.7 Hepatic Impairment

    In patients with impaired liver function, PN solutions containing TRAVASOL should be administered starting at the low end of the dosing range [see Dosage and Administration (2.5)]. Frequent clinical evaluation and laboratory tests to monitor liver function such as bilirubin and liver function parameters should be conducted [see Warnings and Precautions (5.7)].

  • 10 OVERDOSAGE

    An increased infusion rate of PN can cause hypervolemia, electrolyte disturbances, acidosis and/or azotemia, hyperglycemia, hyperosmolality [see Warnings and Precautions (5.5, 5.10)].

    Severe hyperglycemia and severe dilutional hyponatremia, and their complications, can be fatal.

    Discontinue infusion and institute appropriate corrective measures in the event of overhydration or solute overload during therapy, with particular attention to respiratory and cardiovascular systems.

    For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or www.poison.org.

  • 11 DESCRIPTION

    TRAVASOL 10% (amino acids) injection is a sterile, nonpyrogenic hypertonic solution of essential and nonessential amino acids supplied in a flexible container as a Pharmacy Bulk Package. A Pharmacy Bulk Package is a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program [see Dosage and Administration (2.1)]. TRAVASOL is not for direct intravenous infusion.

    The formulas for the individual amino acids found in TRAVASOL are provided in .

    Table 4. Formulas for Amino Acids

    Essential Amino Acids

    Leucine

    (CH3)2 CHCH2CH (NH2) COOH

    Isoleucine

    CH3CH2CH (CH3) CH (NH2) COOH

    Lysine (added as the hydrochloride salt)

    H2N (CH2)4 CH (NH2) COOH

    Valine

    (CH3)2 CHCH (NH2) COOH

    Phenylalanine

    (C6H5) CH2 CH (NH2) COOH

    Histidine

    (C3H3N2) CH2CH (NH2) COOH

    Threonine

    CH3CH (OH) CH (NH2) COO

    Methionine

    CH3S (CH2)2 CH (NH2) COOH

    Tryptophan

    (C8H6N) CH2 CH (NH2) COOH

    Nonessential Amino Acids

    Alanine

    CH3CH (NH2) COOH

    Arginine

    H2NC (NH) NH (CH2)3 CH (NH2) COOH

    Glycine

    H2NCH2COOH

    Proline

    [(CH2)3 NH CH] COOH

    Serine

    HOCH2CH (NH2) COOH

    Tyrosine

    [C6H4 (OH)] CH2CH (NH2) COOH

    TRAVASOL contains no more than 25 µg/L of aluminum.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    TRAVASOL is used as a supplement of nutrition in patients, providing amino acids parenterally.

    The amino acids provide the structural units that make up proteins and are used to synthesize proteins and other biomolecules or are oxidized to urea and carbon dioxide as a source of energy.

  • 15 REFERENCES

    • 1. Ayers P. et al. A.S.P.E.N. Parenteral Nutrition Handbook, 2nd ed. 2014 pg. 123
    • 2. Mueller CM ed. The A.S.P.E.N. Nutrition Support Core Curriculum 2nd ed. 2012. Chapter 29 Wolk R, Foulks C. Renal Disease., pg. 500
  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    TRAVASOL 10% (amino acids) injection is available in plastic Pharmacy Bulk Package flexible containers in the following sizes as shown in Table 5 below.

    Table 5

    Code

    •   Volume

    NDC Number

    1B6623

    •   500 mL

    NDC: 0338-0644-03

    1B6624

    1000 mL

    NDC: 0338-0644-04

    1B6626

    2000 mL

    NDC: 0338-0644-06

    Minimize exposure of TRAVASOL to heat and avoid excessive heat.

    Protect from freezing.

    Store TRAVASOL at room temperature (25ºC/77ºF).

    Do not use if protective overpouch has been previously opened or damaged.

    For storage of admixed solutions [see Dosage and Administration (2.3)].

  • 17 PATIENT COUNSELING INFORMATION

    Inform patients, caregivers, or home healthcare providers of the following risks of TRAVASOL:

  • SPL UNCLASSIFIED SECTION

    Baxter Healthcare Corporation
    Deerfield, IL 60015 USA
    Printed in USA

    Distributed in Canada by
    Baxter Corporation
    Mississauga, ON L5N 0C2

    Baxter and Travasol are trademarks of Baxter International Inc.

    07-19-00-0174

    Rev: November 2017

  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

    Representative Container Label 0338-0644-04

    Container Label

    Container Label

    LOT EXP

    1B6624 1000 mL
    NDC: 0338-0644-04 DIN 00872296

    10% TRAVASOL
    10%
    (Amino Acid)
    Injection

    Pharmacy Bulk Package
    Not For Direct Infusion

    Rx Only

    EACH 100mL CONTAINS ESSENTIAL AMINO ACIDS LEUCINE 730 mg
    ISOLEUCINE 600 mg LYSINE(ADDED AS THE HYDROCHLORIDE SALT) 580 mg VALINE 580 mg PHENYLALANINE 560 mg HISTIDINE 480 mg
    THREONINE 420 mg METHIONINE 400 mg TRYPTOPHAN 180 mg
    NONESSENTIALAMINO ACIDS ALANINE 2.07 g ARGININE 1.15 g
    GLYCINE 1.03 g PROLINE 680 mg SERINE 500 mg TYROSINE 40 mg
    pH ADJUSTED WITH GLACIAL ACETIC ACID pH 6.0 (5.0 TO 7.0)

    mEq/L* ACETATE - 88 CHLORIDE - 40
    *BALANCED BY IONS FROM AMINO ACIDS
    HYPERTONIC OSMOLARITY 998 mOsmo/L (CALC)
    STERILE NONPYROGENIC

    CONTAINS NO MORE THAN 25 µg/L OF ALUMINUM

    ADDITIVES MAY BE INCOMPATIBLE WITH THE FLUID WITHDRAWN
    FROM THIS CONTAINER CONSULT WITH PHARMACIST IF AVAILABLE
    WHEN COMPOUNDING ADMIXTURES USE ASEPTIC TECHNIQUE
    MIX THOROUGHLY DO NOT STORE

    DOSAGE ADMIX FOR INTRAVENOUS ADMINISTRATION AS DIRECTED
    BY A PHYSICIAN SEE ACCOMPANYING DIRECTIONS FOR USE

    ONCE CONTAINERCLOSURE HAS BEEN PENETRATED
    WITHDRAWAL OF CONTENTS SHOULDBE COMPLETED
    WITHOUT DELAY AFFIX ACCOMPANYING LABEL FOR DATE
    AND TIME OF ENTRY DISPENSE CONTENTS WITHIN 4 HOURS
    AFTER INITIAL ENTRY

    CAUTION DO NOT USE UNLESS SOLUTION IS CLEAR AND
    SEAL IS INTACT

    A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY AND
    EFFICACY OF THE PRODUCT

    VIAFLEX CONTAINER

    Baxter Logo
    BAXTER HEALTHCARE CORPORATION
    DEERFIELD IL 60015 USA

    MADE IN THE USA

    PL 146 PLASTIC

    DISTRIBUTED IN CANADA BY
    BAXTER CORPORATION
    MISSISSAUGA ON L5N 0C2

    BAXTER TRAVASOL VIAFLEX
    AND PL 146 ARE TRADEMARKS
    OF BAXTER INTERNATIONAL INC

    RepresentativeTravasol Carton Label 0338-0644-03

    Carton Label

    Carton Label

    Lot: xx
    Qty: 24-500mL

    Exp: x x
    Code: 1B6623

    NDC: 0338-0644-03

    10% Travasol (Amino Acid) INJ Viaflex
    Container

    (17) XX00 (10) xx

    (01) 50303380644037

    07/31/09 10:24:28

    07-35-C

  • INGREDIENTS AND APPEARANCE
    TRAVASOL 
    leucine, phenylalanine, lysine hydrochloride, methionine, isoleucine, valine, histidine, threonine, tryptophan, alanine, glycine, arginine, proline, tyrosine, serine injection
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0338-0644
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    LEUCINE (UNII: GMW67QNF9C) (LEUCINE - UNII:GMW67QNF9C) LEUCINE730 mg  in 100 mL
    PHENYLALANINE (UNII: 47E5O17Y3R) (PHENYLALANINE - UNII:47E5O17Y3R) PHENYLALANINE560 mg  in 100 mL
    LYSINE HYDROCHLORIDE (UNII: JNJ23Q2COM) (LYSINE - UNII:K3Z4F929H6) LYSINE580 mg  in 100 mL
    METHIONINE (UNII: AE28F7PNPL) (METHIONINE - UNII:AE28F7PNPL) METHIONINE400 mg  in 100 mL
    ISOLEUCINE (UNII: 04Y7590D77) (ISOLEUCINE - UNII:04Y7590D77) ISOLEUCINE600 mg  in 100 mL
    VALINE (UNII: HG18B9YRS7) (VALINE - UNII:HG18B9YRS7) VALINE580 mg  in 100 mL
    HISTIDINE (UNII: 4QD397987E) (HISTIDINE - UNII:4QD397987E) HISTIDINE480 mg  in 100 mL
    THREONINE (UNII: 2ZD004190S) (THREONINE - UNII:2ZD004190S) THREONINE420 mg  in 100 mL
    TRYPTOPHAN (UNII: 8DUH1N11BX) (TRYPTOPHAN - UNII:8DUH1N11BX) TRYPTOPHAN180 mg  in 100 mL
    ALANINE (UNII: OF5P57N2ZX) (ALANINE - UNII:OF5P57N2ZX) ALANINE2.07 g  in 100 mL
    GLYCINE (UNII: TE7660XO1C) (GLYCINE - UNII:TE7660XO1C) GLYCINE1.03 g  in 100 mL
    ARGININE (UNII: 94ZLA3W45F) (ARGININE - UNII:94ZLA3W45F) ARGININE1.15 g  in 100 mL
    PROLINE (UNII: 9DLQ4CIU6V) (PROLINE - UNII:9DLQ4CIU6V) PROLINE680 mg  in 100 mL
    TYROSINE (UNII: 42HK56048U) (TYROSINE - UNII:42HK56048U) TYROSINE40 mg  in 100 mL
    SERINE (UNII: 452VLY9402) (SERINE - UNII:452VLY9402) SERINE500 mg  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    ACETIC ACID (UNII: Q40Q9N063P)  
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0338-0644-03500 mL in 1 BAG; Type 0: Not a Combination Product08/23/1984
    2NDC: 0338-0644-041000 mL in 1 BAG; Type 0: Not a Combination Product08/23/1984
    3NDC: 0338-0644-062000 mL in 1 BAG; Type 0: Not a Combination Product08/23/1984
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01893108/23/1984
    Labeler - Baxter Healthcare Corporation (005083209)
    Establishment
    NameAddressID/FEIBusiness Operations
    Baxter Healthcare Corporation189326168ANALYSIS(0338-0644) , MANUFACTURE(0338-0644) , LABEL(0338-0644) , PACK(0338-0644) , STERILIZE(0338-0644)
    Establishment
    NameAddressID/FEIBusiness Operations
    Baxter Healthcare Corporation194684502ANALYSIS(0338-0644)
    Establishment
    NameAddressID/FEIBusiness Operations
    Baxter Healthcare Corporation059140764ANALYSIS(0338-0644)
    Establishment
    NameAddressID/FEIBusiness Operations
    PACE ANALYTICAL INC.362250102ANALYSIS(0338-0644)
    Establishment
    NameAddressID/FEIBusiness Operations
    Baxter SA370353835ANALYSIS(0338-0644) , MANUFACTURE(0338-0644) , LABEL(0338-0644) , PACK(0338-0644) , STERILIZE(0338-0644)

    • Trademark Results [Travasol]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    TRAVASOL
    TRAVASOL
    72439202 0974275 Live/Registered
    BAXTER LABORATORIES, INC.
    1972-10-24
    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.